August 21, 2023

MultiplexDX successfully received a grant from the Research and Innovation Authority

The call, officially announced by the Research and Innovation Authority, aims to support applicants who actively participate in the call announced by the EU framework program for research and innovation Horizon Europe (from now on referred to as "Horizon Europe") in the role of coordinator or partner. Eligible applicants are non-commercial research organizations and enterprises whose project intentions have received at least 50% of the maximum possible evaluation in the call in any of the three pillars of the Horizon Europe program or the calls in the Widening participation and strengthening of the European Research Area program and also in the supplementary Euratom calls.

The participation of Slovak institutions in the EU framework programs for research and innovation is not only below the average of the EU but also of neighboring countries. This call aims to stimulate and increase the participation of institutions from the Slovak Republic in Horizont Europe projects. Its ultimate goal is to increase the overall number of quality projects submitted in the calls to motivate research and innovation capacities in Slovakia to become more actively involved in challenges that enable Slovak researchers and companies to participate in international consortia and support the increase of the long-term potential of Slovak science, research and innovation.

The call also aims to increase the activity of Slovak research organizations in joining international consortia, thus increasing their internationalization and connections with other partners in European or global networks.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News